Collage Venture Partners

Collage Venture Partners is a venture capital firm established in 2021 and located in Miami Beach, Florida. The company specializes in investing in emerging life sciences companies, aiming to support innovative developments in this critical sector. By focusing on early-stage ventures, Collage Venture Partners seeks to identify and nurture opportunities that have the potential to advance healthcare and improve patient outcomes. Through its investments, the firm contributes to the growth and success of companies that are at the forefront of life science innovation.

Nabil Alhakamy Ph.D

Venture Partner

Dexter Pearson

Founding Partner and Partner

4 past transactions

Retension Pharmaceuticals

Series A in 2024
Retension Pharmaceuticals is a healthcare company.Heart disease remains the leading cause of death worldwide. Nearly 50% of adult Americans have elevated blood pressure.

Response Pharmaceuticals

Series A in 2022
Response Pharmaceuticals is a biotechnology and pharmaceutical company focused on developing innovative treatments for the metabolic side effects associated with antipsychotic medications. The company is working on an iMTP inhibitor aimed at addressing weight management and metabolic diseases, thereby facilitating quicker recovery for patients dealing with mental health issues while also combating weight gain and metabolic dysregulation. Through its research and development efforts, Response Pharmaceuticals seeks to improve the quality of life for individuals affected by these conditions.

Bond Biosciences

Series B in 2021
Bond Biosciences, Inc. is a biopharmaceutical company established in 2015 and headquartered in New York. The company specializes in the development of innovative, non-absorbed oral therapeutics aimed at addressing iron overload disorders and other ion-related diseases. By creating small molecule-based chelators that bind excess ions locally in the gastrointestinal tract, Bond Biosciences seeks to offer effective treatment options that allow patients to manage their conditions more simply and effectively. The focus on non-systemic therapies positions the company to provide solutions that minimize systemic side effects while targeting specific health issues related to metal overload.

Bond Biosciences

Series A in 2021
Bond Biosciences, Inc. is a biopharmaceutical company established in 2015 and headquartered in New York. The company specializes in the development of innovative, non-absorbed oral therapeutics aimed at addressing iron overload disorders and other ion-related diseases. By creating small molecule-based chelators that bind excess ions locally in the gastrointestinal tract, Bond Biosciences seeks to offer effective treatment options that allow patients to manage their conditions more simply and effectively. The focus on non-systemic therapies positions the company to provide solutions that minimize systemic side effects while targeting specific health issues related to metal overload.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.